IBI-10090

IBI-10090 · ICON Bioscience Inc

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for IBI-10090, covering 2012-08-16 to 2018-04-23. Get the full timeline:

Most recent: Clinical Trial Update: The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery [Phase 3]